TABLE 2

Baseline characteristics of the ME population

ParameterResult for treatment groupa
250 mg REL + IMI (n = 83)125 mg REL + IMI (n = 87)Placebo + IMI (n = 85)Total (n = 255)
Gender, n (%)
    Female32 (38.6)45 (51.7)37 (43.5)114 (44.7)
    Male51 (61.4)42 (48.3)48 (56.5)141 (55.3)
Race, n (%)
    Asian2 (2.4)3 (3.4)4 (4.7)9 (3.5)
    Black1 (1.2)3 (3.4)0 (0.0)4 (1.6)
    White77 (92.8)78 (89.7)81 (95.3)236 (92.5)
    Multiracial3 (3.6)3 (3.4)0 (0.0)6 (2.4)
    Hispanic or Latino5 (6.0)9 (10.3)1 (1.2)15 (5.9)
Age, yr
    Mean (SD)48.3 (18.4)49.7 (16.4)48.8 (17.7)49.0 (17.4)
    <6565 (78.3)66 (75.9)70 (82.4)201 (78.8)
    ≥6518 (21.7)21 (24.1)15 (17.6)54 (21.2)
Wt, mean (SD) kg79.3 (15.4)77.8 (15.5)79.4 (19.3)78.8 (16.8)
APACHE II score (stratum), n (%)
    ≤1580 (96.4)84 (96.6)81 (95.3)245 (95.1)
    >153 (3.6)3 (3.4)4 (4.7)10 (3.9)
Time of enrollment, n (%)
    Preoperative14 (16.9)17 (19.5)10 (11.8)41 (16.1)
    Postoperative65 (78.3)68 (78.2)72 (84.7)205 (80.4)
    Intraoperative4 (4.8)2 (2.3)3 (3.5)9 (3.5)
Bacteremia with cIAI, n (%)3 (3.6)4 (4.6)3 (3.5)10 (3.9)
  • a REL, relebactam; IMI, 500 mg imipenem-cilastatin.